“…After mucosal administration, LABs and nanoparticles generate mucosal responses against entrapped antigens [ 161 , 162 , 163 , 164 ]. To improve their efficacy, LABs such as lactobacillus have been coupled with DC targeting peptides; alternatively, complement C3d3, anti-CD205, anti-CD11c, or neonatal Fc receptors (FcRn) have been expressed at their surface [ 165 , 166 , 167 , 168 ]. Nanoparticles such as poly(lactic-co-glycolic acid) and liposomes have also been functionalized with anti-DEC-205 [ 169 ], anti-CD40 [ 170 ], anti-mannose receptor [ 171 ], or anti-CD11c [ 172 ] antibodies to target them to DCs.…”